Bactrim
(Cotrimoxazole)Phase 3Small molecule
Co-trimoxazole is an antibiotic combination used to treat bacterial infections and traveler's diarrhea. It works by stopping bacteria from growing in your body.[1] Bactrim is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]
Bactrim is one of 158 small molecule programs targeting Methicillin-Resistant Staphylococcus Aureus Infection. It is currently in Phase 3.
6
Indications
16
Total Trials
1
Active Trials
157
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
547 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Bactrim
UUniversity of California, San Francisco
Phase 3
Jakafi
IncytePreclinical
Neutrexin
WWest Japan Thoracic Oncology Group
Preclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Primsol
CConrado Roberto Hoffmann Filho
Preclinical
Retrovir
BBp Consulting, Inc
Preclinical
Tagamet
DDT MedTech, LLC
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Tylenol
KKenvue Brands
Preclinical
Prograf
VVeloxis Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prophylaxis4 trials
Show 1 more trial
Pregnancy2 trials
Antibiotic Prophylaxis1 trial
Methicillin-Resistant Staphylococcus Aureus Infection1 trial
7 more indications
Idiopathic Pulmonary Fibrosis1 trial
Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
Terminated·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 3·NCT01777737·3 enrolled
Antibiotic Resistance1 trial
CAR1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cotrimoxazole. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details